PBAC's latest decision on Pioglitazone hydrochloride: Recommended with restriction (2007). Considered for Triple oral combination therapy with metformin and a sulfonylurea for the treatment of type 2 diabetes mellitus in patients who have an HbA1c greater than 7% despite maximally tolerated doses of metformin and a sulfonylurea.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2007
Submissions
1
2007 → 2007
Eligible population
Type 2 diabetes mellitus patients who have an HbA1c greater than 7% despite maximally tolerated doses of metformin and a sulfonylurea.
Therapy area
Diabetes
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Efficacy measures (HbA1c, FPG)
Key trials
Dailey GE A (2004)
Comparator
rosiglitazone
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis performed; no ICER calculated